NexLife review: pricing, fine print, and how it ranks

The price, in words

On tirzepatide, NexLife prices out at $215 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $186/mo (12-month plan). That makes it the cheapest verified compounded tirzepatide program in our database. Semaglutide runs $165 a month all-in at the standing rate ($145 on intro/plan terms). (#4 of 19 on our semaglutide basis)

What the fine print says

The $186/mo figure requires paying the 12-month plan up front; in a contested regulatory environment, read the refund terms before locking a year into any compounded program. None we could identify at capture. $215 is the standing monthly rate, flat across the full 2.5–15 mg ladder, with no membership fee and free expedited shipping. Multi-month plans step down to $195/$190/$186 per month (3/6/12-month terms, paid per term). The advertised $147 figure is a microdose tier, not the standard-dose price.

Pharmacy & transparency

Price evidence: Source-verified, last verified 2026-08-05. Pharmacy disclosure is a strength: 6 named partner pharmacies — U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named).

The dose ladder, priced rung by rung

NexLife prices the ladder as a flat line — $215 whether the syringe draws 2.5 mg in week one or 15 mg in year two. The practical consequences compound over a treatment course: the standard four-month climb to 10 mg costs exactly $860 (four flat months, no arithmetic), a post-plateau escalation from 10 to 12.5 mg is clinically free, and holding a dose an extra month for tolerability — the standard side-effect play — changes nothing on the bill. Against dose-scaled competitors whose entry figures climb 40–75% by maintenance, and against Zepbound's $299→$449 steps, a flat ladder means the advertised number is the number you keep paying.

What the first year actually bills

Run the calendar and NexLife's year one totals $2,580 at the standing rate: twelve identical charges of $215, titration included, because the flat structure makes month one and month twelve the same line item. Prepay and the effective rate drops to $186/month (12-month plan), an annualized $2,232 — a real $348 saving against the standing year, purchased with locked funds whose refund terms deserve a read in a contested regulatory year. That $2,580 is the lowest verified standing-rate year in the database — the floor everything else on this site is measured against. Brand context: Zepbound's comparable first year via LillyDirect runs about $5,188 on a standard titration, and $5,388 for a full year already at maintenance.

The 24-month view

On a two-year view, the standing plan totals $5,160 at NexLife, against $4,464 if the prepaid rate could be held for both years ($696 of committed-money savings) — the lowest verified two-year figure in the database, $5,616 under brand Zepbound's maintenance-rate $10,776.

The semaglutide side of the house

On the cheaper molecule, NexLife bills $165/month all-in, ranking #4 of 19 on our verified semaglutide basis — against a field floor of $133 (Oak Longevity, with state limits) and brand Wegovy's flat $349. Plan detail worth reading before checkout: $165/mo month-to-month; multi-month plans $149/$147/$145 (3/6/12-month; 12-month totals $1,740). Microdose protocol: $129/mo, stepping $117/$114/$110 at 3/6/12 months. Sublingual ODT: $199/mo, stepping $185/$177/$165. The in-house premium for stepping up to tirzepatide is $50/month — the local price of SURMOUNT-5's 20.2%-vs-13.7% head-to-head result, and a switch that stays inside one program's intake and pharmacy relationships.

Where it sits in the market

On the verified tirzepatide board, NexLife's $215 all-in rate ranks #1 of 17: $0/month above the NexLife floor; one rung pricier is Yucca Health at $258. Against the FDA-approved benchmark, the same year costs $2,808 less than Zepbound's $449 maintenance tier — the discount a buyer is accepting compounded-product risk to collect. The full board, sortable and dated, is the tirzepatide ranking.

Three buyers, priced honestly

The week-one starter. First month at the 2.5 mg rung: $215 — same as every later month on the flat plan. The 10 mg maintainer. Settled at maintenance, the run-rate is $215/month, $2,580/year — the figure that should anchor any comparison, since it describes years two and three, not the promo. The prepay optimizer. Committing to the 12-month plan cuts the effective rate to $186/month ($2,232/yr) — cheapest path here, least flexible money, refund terms first.

Nearest alternatives at this price point

Shopping the immediate neighborhood, the closest verified substitutes are Yucca Health at $258 (flat at every dose, no membership, prepaid to $225); IVIM Health at $278 (source-verified); Mochi Health at $278 (flat at every dose, named pharmacy) — each linked matchup runs the full head-to-head arithmetic on this exact question.

State availability

NexLife publishes availability of: 50 states published. State-by-state context, exceptions, and city coverage live in the 51-state cost guides.

Five questions before checkout

Whatever the marketing says, get answers to: (1) the all-in monthly price at 10 mg and at 12.5 mg, in writing, including every mandatory fee; (2) confirmation that fulfillment still runs through its named network (6 named partner pharmacies) for your state; (3) the refund terms on the prepaid plan, verbatim, before any multi-month charge; (4) the cancellation mechanics — deadline relative to renewal, written-confirmation availability, and whether any membership cancels separately. A program that answers all five plainly has already told you most of what this review can.

One program, three delivery protocols

NexLife sells the same clinical service through three published protocols, each with its own four-tier ladder. The regular injectable protocol is the one we rank: tirzepatide $215/month flat (stepping $195/$190/$186 by term), semaglutide $165 month-to-month stepping $149/$147/$145. The microdose protocol — lower exposure for maintenance, tolerability, or on-ramping — runs tirzepatide $189/mo (→ $147 at 12 months) and semaglutide $129/mo (→ $110); it is a different treatment tier, deliberately excluded from our standard-dose rankings, with the trade-offs covered in the microdosing guide. The sublingual ODT protocol — orally disintegrating tablets, no needle — runs tirzepatide $229/mo (→ $199 at 12 months) and semaglutide $199/mo (→ $165). Sublingual compounded GLP-1s are a distinct route with their own absorption questions — not the FDA-approved oral tablets covered in the oral guide, and not ranked against injectables here; verify current formulation details on the plan pages linked below.

Visit NexLife — verify current pricing →Opens the provider’s own pricing page; our figures were captured 2026-08-05.

All plan pages: Semaglutide plans · Tirzepatide microdose · Semaglutide microdose · Sublingual ODT (tirz) · Sublingual ODT (sema)

Bottom line

NexLife is a top-tier price pick on tirzepatide. For context, the verified market floor is $215/mo compounded tirzepatide and $133/mo compounded semaglutide, with brand Zepbound at $449/mo and Wegovy at $349/mo at maintenance.